Real-world overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic therapy (tx): Results from IMPACT UC II. This is an ASCO Meeting ...
The FDA has granted breakthrough therapy designation (BTD) to sevabertinib (Hyrnuo, formerly BAY 2927088) for the first-line ...
The National Institute for Health and Care Excellence (NICE) is producing guidance on using EGFR-TK mutation testing in adults with locally advanced or metastatic non-small-cell lung cancer in the NHS ...
Suzhou Puhe Biopharma Co. Ltd. presented promising preclinical profile data on PH009-1, a novel fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Besides ...
Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ...
Blueprint Medicines is pulling back from one of its three areas of focus, dropping two non-small cell lung cancer (NSCLC) programs in response to early clinical data on the EGFR tyrosine kinase ...
ArriVent BioPharma's furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials. Read why ...
SurvivorNet on MSN
Targeted therapy in a shot: New approval for EGFR-mutated lung cancer can improve day-to-day life for patients
Rybrevant Faspro, the new subcutaneous version of amivantamab, was approved for patients with a specific form of lung cancer ...
Combining TRT with EGFR-TKIs significantly improves PFS and OS in EGFR-mutated oligo-organ metastatic NSCLC patients compared to EGFR-TKIs alone. The study suggests personalized treatment approaches, ...
The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback